Recaticimab

DB19302InvestigationalProtein Based Therapies

Recaticimab is under investigation in clinical trial NCT06467617 (Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC).

Mechanism: Pharmacologically active on Proprotein convertase subtilisin/kexin type 9
Curator reviewed
Code names: SHR-1209

Resolves to

Compound

UNII20IE6M67UXCAS2361290-85-7

Targets

Q8NBP7PCSK9

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Recaticimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account